When was Actithera founded?

Actithera was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Actithera located?

Actithera is headquartered in Cambridge, United States.

Who is the current CEO of Actithera?

Andreas Goutopoulos of Actithera. They have also founded 1 company.

How many employees does Actithera have?

As of Sep 30, 2026, the latest employee count at Actithera is 38.

Is Actithera a funded company?

Actithera is a funded company, having raised a total of $80.8M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 01, 2023.

When was the latest funding round of Actithera?

Actithera's latest funding was a $***** Series A round on Jul 09, 2025, with participation from 9 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.54B in funding in 2026 to date.

Where does Actithera rank among its competitors?

Actithera ranks 267th amongst 2573 active competitors, of which 867 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Actithera?

Actithera's top competitors include Jazz Pharmaceuticals, Tango Therapeutics and Syndax. Among them, Immuneel secured the most recent funding round in June, 2026.

Actithera - 2026 Company Profile, Team, Funding & Competitors

Company Details

Actithera is a radiopharmaceutical company developing novel radiotherapeutics for cancer treatment. Leveraging a unique medicinal chemistry approach, the company aims to discover and develop theranostics with prolonged tumor retention. With a strong focus on precision medicine, Actithera is poised to revolutionize the treatment of cancer through targeted radiotherapy.

Website: actithera.com
Email ID: *****@actithera.com
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Cambridge, United States

Stage

Series A

Total Funding

$80.8M in 2 rounds

Latest Funding Round

Series A, Jul 09, 2025, $*****

Investors

M Ventures & 8 more

Ranked

267^th among 2573 active competitors

Employee Count

38 as on Sep 30, 2026

Similar Companies

RayzeBio & 111 more

View Actithera's full profile

Actithera is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ACTITHERA, INC. CIN: 4490934 , United States, Active	Apr 09, 2021	-	-	-

Actithera has raised a total funding of $80.8M over 2 rounds. Its first funding round was on Apr 01, 2023. Its latest funding round was a Series A round on Jul 09, 2025 for $*****. 9 investors participated in its latest round. Actithera has 9 institutional investors.

Here is the list of recent funding rounds of Actithera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 09, 2025	7705681	Series A	5611220	3484144	8006175	9408681
Apr 01, 2023	2359459	Seed	3020016	8627045	M Ventures	Arkin

Access funding benchmarks and valuations. Sign up today!

View details of Actithera's funding rounds and investors

The founders of Actithera is Andreas Goutopoulos. Andreas Goutopoulos is the CEO of Actithera.

Here are the details of Actithera's key team members:

Andreas Goutopoulos: Co-Founder & CEO of Actithera.
Contact Info: 1 email address

View details of Actithera's Founder profiles and Board Members

Actithera's employee count trend

Actithera has 38 employees as of Sep 26. Here is Actithera's employee count trend over the years:

Uncover Actithera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Actithera include Jazz Pharmaceuticals, Tango Therapeutics and Syndax. Here is the list of Top 10 competitors of Actithera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
3rd	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
4th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
5th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
7th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
8th	RayzeBio 2019, San Diego (United States), Acquired	R&D company focused on manufacturing of cancer drugs	$426M	Venrock, VenBio & 22 others	70/100
9th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
267th	Actithera 2021, Cambridge (United States), Series A	Radiopharmaceutical company developing novel radiotherapeutics for the treatment of cancer through its unique medicinal chemistry platform	$80.8M	4Bio Capital, Surveyor Capital & 7 others	56/100